Edward J Rayner
Ed was pointed to the Board of Directors in September 2018. He has over 20 years’ experience in global capital markets and is currently investment director at Arix Bioscience plc based in London.
Before joining Arix Bioscience at its inception, Ed spent 18 years as an equity analyst and portfolio manager in Europe and Australia. From 2004 to 2014, he was based in Sydney Australia, initially as a head of research at Alliance Bernstein and then a senior portfolio manager at AMP Capital where he managed the growth equity portfolios and launched a small companies fund. As part of his responsibilities he focused on the healthcare sector.
Prior to his move to Australia, Ed analysed European equities at UBS Asset Management and JP Morgan Investment Management.
Ed is currently a non-executive director of Depixus SAS, an unlisted French biotech; and Simbec Orion Group, an unlisted global clinical contract research organisation headquartered in the United Kingdom.
Ed holds an MA in Chemistry and MSc in Management both from the University of Oxford and is a Chartered Financial Analyst.